

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A)
(Stock code: 9989)

**VOLUNTARY ANNOUNCEMENT ENTERING INTO LICENSE AND
DISTRIBUTION AGREEMENT WITH OEP**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

As at March 27, 2023, Shenzhen OncoVent Biomedical Technology Co., Ltd. (“**OncoVent Biomedical**”), a majority-controlled subsidiary of the Company, signed a license agreement with Orient EuroPharma Co., Ltd. (“**OEP**”), pursuant to which OncoVent Biomedical agreed to grant exclusive rights to OEP, which will be responsible for the commercialization of Oregovomab, an immunotherapy drug candidate, in Taiwan, including related regulatory applications and necessary clinical trials, and to grant OEP a pre-emptive right of exclusive sale, marketing and distribution rights of Oregovomab in Hong Kong and Macau.

OncoVent Biomedical is entitled to a number of payments from OEP under the license agreement, including a one-off non-refundable down payment upon the effective date of the license agreement, a regulatory milestone payment upon achievement of a regulatory approval milestone and a commercial milestone payment upon achievement of a sales milestone. OEP also agreed to purchase Oregovomab from OncoVent Biomedical at a price equal to an agreed percentage to the average sale price of Oregovomab in Taiwan in the future.

Oregovomab, a murine monoclonal antibody and an anti-CA125 immunotherapy first-in-class drug candidate, has completed a Phase II clinical trial as a first-line treatment with standard chemotherapy in patients with advanced primary ovarian cancer. The results of the Phase II clinical trial have shown the safety and efficacy of Oregovomab in such combined standard treatment regime for advanced primary ovarian cancer patients were in line with efficacy expectations. The Phase II clinical results have shown a significant prolongation of median progression-free survival (PFS) of 41.8 months in such combined standard treatment regime, compared with 12.2 months in chemotherapy-only regime with an HR of 0.46 (95% CI: 0.28, 0.77). It also showed a significant improvement in overall survival (OS) with an HR of 0.35 (95% CI: 0.16, 0.76). Oregovomab has obtained Orphan Drug Designation from the United States Food and Drug Administration and the European Medicines Agency.

The first patient in a Phase III clinical trial of Oregovomab was dosed in the United States in 2020. This global pivotal trial is expected to enroll 602 patients from 190 clinical sites in 17 countries. As at the date of the announcement, the Phase III clinical trial of Oregovomab has included 534 subjects globally, of which 21 subjects were from Taiwan.

BENEFITS AND IMPACTS TO THE COMPANY

The Company believes that the strategic collaboration between OncoVent Biomedical and OEP under the license agreement will maximize the potential value of Oregovomab in the region and enable the Group to explore the market potential of Oregovomab, advance the clinical development and regulatory registration of the licensed product with the support of OEP, thereby accelerating the pace of commercialization, and striving to provide a new treatment option for patients with primary ovarian cancer as soon as possible. During the clinical study phase, Oregovomab is manufactured by Cytovance Biologics, Inc., a wholly-owned subsidiary of the Company, to ensure high quality delivery of the drug and to form a ring-fenced industrial chain in the Company, thus enabling better synergy within the Company.

Under the terms of the license agreement, OncoVent Biomedical will be entitled to various payments, which will have a positive impact on production and operation. At the same time, through the cooperation with OEP, the development and registration costs of Oregovomab can be significantly reduced, and by leveraging OEP's established sales system and network, the marketing of the drug can be effectively realized, thus reflecting the value and return of the innovative drug. The terms of the license agreement are fair and reasonable and in the interests of the Company and all of its shareholders as a whole.

We believe that the strategic collaboration between OncoVent Biomedical and OEP demonstrates the Company's forward-looking strategic vision and deployment capability in the field of innovative drugs, and the selection of Oregovomab is a recognition of the potential and value of the product by OEP based on the Taiwan market. Leveraging on this strategic cooperation, Hepalink will continue to actively explore further cooperation opportunities, accelerate the strategic layout of innovative drugs and build up diversified commercialization capabilities.

INFORMATION ON OEP

Established in 1982 and officially listed on the Taipei Exchange in 2003, OEP provides prescription drugs, cancer drugs, nutrition and healthcare for young children and adults, medical and beauty care and other products. It has research and development centers in Taiwan and the United States, and two pharmaceutical factories in Taiwan for U.S. FDA-approved oral finished doses and highly allergenic injections. It is a multinational pharmaceutical manufacturer with research and development, production and sales capabilities as well as sales teams covering Southeast Asia, Hong Kong, Mainland China and the United States. With over 20 years of experience in the cancer field and solid business and sales teams in Taiwan, Hong Kong, Singapore, the Philippines and Malaysia, OEP currently sells cancer drugs such as “Vinorelbine” oral capsules for non-small cell lung cancer and breast cancer, and “Pamorelin” long-acting injections for prostate cancer.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
March 27, 2023